Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel with Reduced Dose Lymphodepletion in Metastatic Melanoma
NCT06151847Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lifileucel in melanoma, sponsored by University of Kansas Medical Center. Primary endpoint: Percentage of total T-cell receptor (TCR) populations shared between the TIL product and peripheral blood mononuclear cells (PBMCs) at 42 days. Started Dec 2023; status: completed.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06151847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151847.